Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs for treatment-resistant cancers. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.
Follow-Up Questions
What is the price performance of SCPS stock?
The current price of SCPS is $0.0003, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Scopus Biopharma Inc?
Scopus Biopharma Inc belongs to Biotechnology industry and the sector is Health Care
What is Scopus Biopharma Inc market cap?
Scopus Biopharma Inc's current market cap is $12623.999999999998
Is Scopus Biopharma Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Scopus Biopharma Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
